ES2193003A1 - Uso dermatologico y preparacion dermatologica. - Google Patents

Uso dermatologico y preparacion dermatologica.

Info

Publication number
ES2193003A1
ES2193003A1 ES200250061A ES200250061A ES2193003A1 ES 2193003 A1 ES2193003 A1 ES 2193003A1 ES 200250061 A ES200250061 A ES 200250061A ES 200250061 A ES200250061 A ES 200250061A ES 2193003 A1 ES2193003 A1 ES 2193003A1
Authority
ES
Spain
Prior art keywords
dermatological
preparation
triiodothyronine
thyroxine
thyroid hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200250061A
Other languages
English (en)
Other versions
ES2193003B1 (es
Inventor
Pekka Heino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsat Therapies Oy
Original Assignee
Ipsat Therapies Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsat Therapies Oy filed Critical Ipsat Therapies Oy
Publication of ES2193003A1 publication Critical patent/ES2193003A1/es
Application granted granted Critical
Publication of ES2193003B1 publication Critical patent/ES2193003B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a un uso dermatológico, una preparación dermatológica y un procedimiento para inhibir o reducir la actividad de hormona tiroidea de L-tiroxina y su metabolito L-triyodotironina, que aceleran el metabolismo y la proliferación celular. Se usa una preparación farmacéutica tópica que contine un derivado de tironina que inhibe la actividad de hormona tiroidea de L-tiroxina y L-triyodotironina.
ES200250061A 2000-04-06 2001-02-05 Uso dermatologico y preparacion dermatologica. Expired - Fee Related ES2193003B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20000818 2000-04-06
FI20000818A FI107018B (fi) 2000-04-06 2000-04-06 Dermatologinen käyttö ja valmiste

Publications (2)

Publication Number Publication Date
ES2193003A1 true ES2193003A1 (es) 2003-10-16
ES2193003B1 ES2193003B1 (es) 2005-02-01

Family

ID=8558139

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200250061A Expired - Fee Related ES2193003B1 (es) 2000-04-06 2001-02-05 Uso dermatologico y preparacion dermatologica.

Country Status (14)

Country Link
US (2) US20030144359A1 (es)
EP (1) EP1274416A1 (es)
JP (1) JP2003530349A (es)
AU (1) AU2001235506A1 (es)
CA (1) CA2405425A1 (es)
CH (1) CH695983A5 (es)
DE (1) DE10196025T1 (es)
DK (1) DK200201483A (es)
ES (1) ES2193003B1 (es)
FI (1) FI107018B (es)
GB (1) GB2377380B (es)
NO (1) NO20024810L (es)
SE (1) SE0202886L (es)
WO (1) WO2001076589A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0831769T3 (da) * 1995-06-07 2004-02-23 Karobio Ab Hidtil ukendte anvendelser af thyroideahormoner eller thyroideahormon-lignende forbindelser
CA2539288C (en) 2003-09-15 2015-05-12 Shaker A. Mousa Thyroid hormone analogs and methods of use
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US9220788B2 (en) 2009-06-17 2015-12-29 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
WO2007035612A2 (en) 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
EP2120913B1 (en) 2006-12-22 2015-01-21 NanoPharmaceuticals LLC Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US20100159021A1 (en) * 2008-12-23 2010-06-24 Paul Davis Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use
US9180107B2 (en) 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
US10201616B2 (en) 2016-06-07 2019-02-12 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB859546A (en) * 1956-05-29 1961-01-25 Arthur Alfred Hellbaum Composition for treatment of the skin
US3198702A (en) * 1960-03-17 1965-08-03 Arthur A Hellbaum Method for treating skin burns
WO1996040048A2 (en) * 1995-06-07 1996-12-19 Karo Bio Ab Novel uses for thyroid hormones or thyroid hormone-like compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09509428A (ja) * 1994-02-23 1997-09-22 カイロン コーポレイション 薬理学的に活性な薬剤の血清半減期を増加させるための方法および組成物
US6380255B1 (en) * 1995-06-07 2002-04-30 Karo Bio Ab Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds
HUT75956A (en) * 1995-11-29 1997-05-28 Cyclolab Pharmaceutical composition containing thyroxine
US5951989A (en) * 1997-04-07 1999-09-14 Heymann; Warren R. Method for the treatment of dry skin
GB9828442D0 (en) * 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
WO2000064431A1 (en) * 1999-04-26 2000-11-02 Danforth Elliot Jr Pharmaceutical compositions of tetrac and methods of use thereof
US6716877B2 (en) * 2001-01-31 2004-04-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB859546A (en) * 1956-05-29 1961-01-25 Arthur Alfred Hellbaum Composition for treatment of the skin
US3198702A (en) * 1960-03-17 1965-08-03 Arthur A Hellbaum Method for treating skin burns
WO1996040048A2 (en) * 1995-06-07 1996-12-19 Karo Bio Ab Novel uses for thyroid hormones or thyroid hormone-like compounds

Also Published As

Publication number Publication date
DK200201483A (da) 2002-10-03
CA2405425A1 (en) 2001-10-18
GB2377380A (en) 2003-01-15
GB2377380B (en) 2004-07-14
US20050272817A1 (en) 2005-12-08
NO20024810D0 (no) 2002-10-04
CH695983A5 (de) 2006-11-15
GB0222880D0 (en) 2002-11-13
SE0202886D0 (sv) 2002-10-01
SE0202886L (sv) 2002-12-02
FI107018B (fi) 2001-05-31
JP2003530349A (ja) 2003-10-14
DE10196025T1 (de) 2003-03-13
AU2001235506A1 (en) 2001-10-23
EP1274416A1 (en) 2003-01-15
FI20000818A0 (fi) 2000-04-06
US20030144359A1 (en) 2003-07-31
ES2193003B1 (es) 2005-02-01
WO2001076589A1 (en) 2001-10-18
NO20024810L (no) 2002-12-06

Similar Documents

Publication Publication Date Title
ES2193003A1 (es) Uso dermatologico y preparacion dermatologica.
AR031473A1 (es) Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
ES2162517T3 (es) Composicion farmaceutica que comprende una combinacion de metformin y fibrato y su uso en la preparacion de medicamentos destinados a reducir la hiperglicemia.
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
EE9900037A (et) Sisselõikuv kruvi, eriti betoonikruvi
ES2157307T3 (es) Composicion topica que contiene un antagonista de sustancia p.
ES2192227T3 (es) Composiciones farmaceuticas orales con liberacion retardada de inhibidores reversibles de las bombas de protones.
PE20020598A1 (es) Combinacion de agonistas de gaba e inhibidores de aldosa-reductasa
AR018924A1 (es) Composicion para la prevencion y/o tratamiento de osteoporosis y alteraciones debidas al sindrome de menopausia
AR017205A1 (es) ANILIDAS MIMÉTICAS DE ÁCIDO RETINOICO, PROCESOS PARA PREPARAR DICHOS COMPUESTOS, COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN, UN PROCESO PARA PREPARAR DICHAS COMPOSICIONES Y EL USO DE DICHOS COMPUESTOS EN LA ELABORACIoN DE MEDICAMENTOS.
NO20070488L (no) Aktiv forbindelse inneholdende faste, stopte former for ekstern anvendelse overfor parasitter pa dyr
ES2184408T3 (es) Sistema transdermico que contiene un antioxidante.
ES2170918T3 (es) Inhibidor de proteina quinasa c sustituidos con halo.
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
BR9914799A (pt) Sistema conservante para composições farmacêuticas administráveis topicamente contendo um sabão de ácido graxo/aminoácido
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
MXPA03004209A (es) Composicion farmaceutica o cosmetica y uso de un inhbidor de proteina cinasa c con un inhibidor de metaloproteasas de la matriz para inhibir la migracion de celulas de langerhans.
PA8469101A1 (es) Ligandos azabiciclicos de receptores 5ht1
ES2156220T3 (es) Preparacion transdermica que contiene un metabolito de loratidina con accion antihistaminica.
CR6398A (es) Antagonistas de 5ht1 para terapia antidepresiva
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
AR042712A1 (es) Uso de inhibidores de quinurenina 3- hidroxilasa para el tratamiento de la diabetes por incremento de la cantidad de celulas de los islotes de langerhans
ES2174297T3 (es) Nuevos derivados de piranosidos.
HN2000000056A (es) Nuevas formas cristalinas de un antibiotico macrolido

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20031016

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2193003B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180808